BeOne Medicines hits $1.1B in Brukinsa sales as global revenue surges 35%
BeOne Medicines (NASDAQ:ONC) delivered a record-breaking first quarter for 2026, as the global oncology specialist saw its flagship therapy, Brukinsa (zanubrutinib), cement its status as a leading treatment in the BTK inhibitor market.























